Table 1

General condition of 62 primary CSCLC patients, n (%)

CharacteristicsEP/CE groupTEP/TCE groupχ2P
Age (years)0.4330.551
 >6022 (51.2)8 (42.1)
 ≤6021 (48.8)11 (57.9)
Gender0.0000.991
 Male34 (79.1)15 (78.9)
 Female9 (20.9)4 (21.1)
Smoking index0.5870.444
 >40025 (58.1)13 (68.4)
 ≤40018 (41.9)6 (31.6)
KPS2.9350.087
 >8037 (86.1)19 (100.0)
 ≤806 (3.9)0 (0.0)
Stage2.4920.571
 I4 (9.3)1 (5.3)
 II3 (7.0)2 (10.5)
 III15 (34.9)10 (52.6)
 IV21 (48.8)6 (31.6)
No. of chemotherapy cycles6.1730.103
 1-2 cycles5 (11.6)7 (36.8)
 3-4 cycles15 (34.9)3 (15.8)
 5-6 cycles19 (44.2)7 (36.8)
 >6 cycles4 (9.3)2 (10.5)
First-line chemotherapy1.8970.168
 Platinum
 Cisplatin19 (44.2)12 (63.2)
 Carboplatin24 (55.8)7 (36.8)
 Chest radiotherapy12 (27.9)5 (26.3)0.0170.897
 Prophylactic cranial radiotherapy (PCI)8 (18.6)1 (5.3)1.8900.169
 Surgical resection9 (20.9)6 (31.6)0.8150.367
Second-line chemotherapy3.2170.522
 No treatment4 (14.3)3 (42.9)
 IP regime8 (28.6)1 (14.3)
 The original regimen6 (21.4)1 (14.3)
 TP regimen7 (25.0)1 (14.3)
 Local radiotherapy3 (10.7)1 (14.3)
Third-line chemotherapy8 (18.6)2 (10.5)0.6360.425

Smoking index: (number of cigarettes smoked per day) × years. CSCLC, combined small-cell lung cancer; KPS, Karnofsky Performance Status; IP regimen, irinotecan plus platinum; TP regimen, paclitaxel plus platinum.